- Type / Class
- Equity / Common Stock
- Shares outstanding
- 131,352,709
- Total 13F shares
- 99,996,517
- Share change
- +15,953,105
- Total reported value
- $4,993,540,992
- Put/Call ratio
- 414%
- Price per share
- $49.94
- Number of holders
- 194
- Value change
- +$865,860,362
- Number of buys
- 141
- Number of sells
- 63
Quarterly Holders Quick Answers
What is CUSIP 92243G108?
CUSIP 92243G108 identifies PCVX - Vaxcyte, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92243G108:
Top shareholders of PCVX - Vaxcyte, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
9%
|
11,808,565
|
$442,585,026 | — | 31 Mar 2023 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
5.6%
|
7,291,254
|
$273,276,200 | — | 31 Mar 2023 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
5.4%
|
7,127,611
|
$267,146,529 | — | 31 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
5%
|
6,532,316
|
$244,831,203 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
3.9%
|
5,081,865
|
$190,468,300 | — | 31 Mar 2023 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.5%
|
3,239,274
|
$121,407,989 | — | 31 Mar 2023 | |
| STATE STREET CORP |
13F
|
Company |
2.3%
|
3,076,016
|
$115,289,080 | — | 31 Mar 2023 | |
| Capital Research Global Investors |
13F
|
Company |
2.2%
|
2,853,006
|
$106,930,665 | — | 31 Mar 2023 | |
| Carlyle Group Inc. |
13F
|
Company |
1.5%
|
1,923,158
|
$72,079,962 | — | 31 Mar 2023 | |
| Medicxi Ventures Management (Jersey) Ltd |
13F
|
Company |
1.1%
|
1,457,300
|
$54,619,604 | — | 31 Mar 2023 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
1.1%
|
1,430,039
|
$53,597,863 | — | 31 Mar 2023 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.1%
|
1,397,405
|
$52,374,739 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1%
|
1,329,339
|
$49,823,638 | — | 31 Mar 2023 | |
| BRAIDWELL LP |
13F
|
Company |
1%
|
1,319,978
|
$49,472,775 | — | 31 Mar 2023 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1%
|
1,313,642
|
$49,235,000 | — | 31 Mar 2023 | |
| Kynam Capital Management, LP |
13F
|
Company |
0.93%
|
1,216,784
|
$45,605,064 | — | 31 Mar 2023 | |
| TPG GP A, LLC |
13F
|
Company |
0.91%
|
1,190,336
|
$44,613,793 | — | 31 Mar 2023 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.89%
|
1,170,000
|
$43,851,600 | — | 31 Mar 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.65%
|
854,110
|
$32,012,043 | — | 31 Mar 2023 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.64%
|
844,778
|
$31,662,279 | — | 31 Mar 2023 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.61%
|
794,907
|
$29,793,114 | — | 31 Mar 2023 | |
| Novo Holdings A/S |
13F
|
Company |
0.57%
|
745,000
|
$27,922,600 | — | 31 Mar 2023 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.56%
|
733,907
|
$27,507,000 | — | 31 Mar 2023 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.56%
|
729,439
|
$27,339,374 | — | 31 Mar 2023 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.55%
|
716,239
|
$26,844,628 | — | 31 Mar 2023 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
0.53%
|
693,039
|
$25,975,102 | — | 31 Mar 2023 | |
| PICTET ASSET MANAGEMENT SA |
13F
|
Company |
0.51%
|
670,084
|
$25,114,748 | — | 31 Mar 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
668,302
|
$25,047,959 | — | 31 Mar 2023 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.5%
|
659,211
|
$24,707,228 | — | 31 Mar 2023 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.47%
|
613,906
|
$23,009,197 | — | 31 Mar 2023 | |
| Jeff Fairman |
3/4/5
|
VP, Research |
—
mixed-class rows
|
369,054
mixed-class rows
|
$22,935,618 | — | 30 Dec 2022 | |
| Vivo Capital, LLC |
13F
|
Company |
0.44%
|
579,508
|
$21,719,960 | — | 31 Mar 2023 | |
| Avidity Partners Management LP |
13F
|
Company |
0.39%
|
510,000
|
$19,114,800 | — | 31 Mar 2023 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.38%
|
501,100
|
$18,781,228 | — | 31 Mar 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.38%
|
498,351
|
$18,678,195 | — | 31 Mar 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.37%
|
487,633
|
$18,276,485 | — | 31 Mar 2023 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.33%
|
435,000
|
$16,303,800 | — | 31 Mar 2023 | |
| Nicholas Investment Partners, LP |
13F
|
Company |
0.33%
|
433,800
|
$16,258,824 | — | 31 Mar 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.32%
|
420,877
|
$15,774,000 | — | 31 Mar 2023 | |
| NORGES BANK |
13F
|
Company |
0.32%
|
416,636
|
$15,615,517 | — | 31 Mar 2023 | |
| Polar Asset Management Partners Inc. |
13F
|
Company |
0.31%
|
413,300
|
$15,490,484 | — | 31 Mar 2023 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.3%
|
393,249
|
$14,738,973 | — | 31 Mar 2023 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.29%
|
380,250
|
$14,251,770 | — | 31 Mar 2023 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.26%
|
337,755
|
$12,659,057 | — | 31 Mar 2023 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.23%
|
301,046
|
$11,283,204 | — | 31 Mar 2023 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.23%
|
300,000
|
$11,244,000 | — | 31 Mar 2023 | |
| Eversept Partners, LP |
13F
|
Company |
0.23%
|
299,050
|
$11,208,394 | — | 31 Mar 2023 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.22%
|
295,000
|
$11,056,600 | — | 31 Mar 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.22%
|
292,896
|
$10,977,000 | — | 31 Mar 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.22%
|
284,109
|
$10,648,404 | — | 31 Mar 2023 |
Institutional Holders of Vaxcyte, Inc. - Common Stock (PCVX) as of Q2 2023
As of 30 Jun 2023,
Vaxcyte, Inc. - Common Stock (PCVX) was held by
194 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
99,996,517 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., JANUS HENDERSON GROUP PLC, WELLINGTON MANAGEMENT GROUP LLP, Capital Research Global Investors, STATE STREET CORP, FRED ALGER MANAGEMENT, LLC, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
194
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
186
Q2 2023 holders
194
Holder diff
8
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.